COHANCE LIFESCIENCES
|
COHANCE LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 4.68 | 19.14 | 11.79 | 16.16 | 17.83 |
| CEPS(Rs) | 8.82 | 25.57 | 13.94 | 18.04 | 19.36 |
| DPS(Rs) | - | - | - | 6.00 | 5.00 |
| Book NAV/Share(Rs) | 101.76 | 140.10 | 80.47 | 68.16 | 59.99 |
| Tax Rate(%) | 27.49 | 24.65 | 25.98 | 26.52 | 32.02 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.82 | 30.56 | 38.60 | 42.80 | 44.03 |
| EBIT Margin(%) | 10.77 | 26.21 | 39.29 | 42.68 | 51.18 |
| Pre Tax Margin(%) | 9.13 | 24.64 | 38.59 | 41.72 | 50.53 |
| PAT Margin (%) | 6.62 | 18.56 | 28.56 | 30.66 | 34.35 |
| Cash Profit Margin (%) | 14.88 | 24.96 | 33.75 | 34.24 | 37.31 |
| Performance Ratios | |||||
| ROA(%) | 2.68 | 12.52 | 13.76 | 20.18 | 25.62 |
| ROE(%) | 4.02 | 17.25 | 15.87 | 25.21 | 33.52 |
| ROCE(%) | 6.12 | 22.80 | 21.22 | 33.41 | 45.92 |
| Asset Turnover(x) | 0.40 | 0.67 | 0.48 | 0.66 | 0.75 |
| Sales/Fixed Asset(x) | 0.57 | 1.11 | 1.17 | 1.71 | 2.09 |
| Working Capital/Sales(x) | 1.97 | 2.48 | 0.93 | 1.57 | 1.44 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.77 | 0.90 | 0.86 | 0.58 | 0.48 |
| Receivable days | 116.90 | 63.37 | 42.46 | 47.25 | 46.80 |
| Inventory Days | 82.83 | 48.87 | 94.43 | 81.11 | 66.93 |
| Payable days | 153.58 | 69.70 | 65.80 | 79.70 | 87.45 |
| Valuation Parameters | |||||
| PER(x) | 64.45 | 60.59 | 57.37 | 29.26 | 34.66 |
| PCE(x) | 34.23 | 45.36 | 48.54 | 26.20 | 31.91 |
| Price/Book(x) | 2.97 | 8.28 | 8.41 | 6.93 | 10.30 |
| Yield(%) | - | - | - | 1.27 | 0.81 |
| EV/Net Sales(x) | 5.14 | 11.38 | 16.37 | 8.98 | 11.95 |
| EV/Core EBITDA(x) | 25.29 | 34.27 | 36.80 | 19.39 | 23.41 |
| EV/EBIT(x) | 47.73 | 43.42 | 41.67 | 21.02 | 23.34 |
| EV/CE(x) | 2.86 | 7.60 | 8.24 | 6.67 | 9.72 |
| M Cap / Sales | 5.09 | 11.32 | 16.38 | 8.98 | 11.92 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -13.03 | 148.11 | -21.56 | 1.52 | 30.75 |
| Core EBITDA Growth(%) | -46.77 | 85.21 | -24.63 | -7.95 | 47.43 |
| EBIT Growth(%) | -64.27 | 65.49 | -27.84 | -15.32 | 41.05 |
| PAT Growth(%) | -69.00 | 61.26 | -26.99 | -9.37 | 25.24 |
| EPS Growth(%) | -75.53 | 62.30 | -27.00 | -9.37 | 25.24 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.04 | 0.07 | 0.02 | 0.04 | 0.06 |
| Current Ratio(x) | 2.78 | 2.49 | 10.67 | 3.81 | 3.64 |
| Quick Ratio(x) | 1.91 | 1.83 | 8.71 | 2.78 | 2.82 |
| Interest Cover(x) | 6.56 | 16.65 | 55.45 | 44.69 | 79.29 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | - | 0.01 | 0.01 |
Compare Financial Ratios of peers of COHANCE LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| COHANCE LIFESCIENCES | ₹17,241.9 Cr | 0.4% | 5.9% | -48.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹460,696.0 Cr | 0.5% | -4% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,063.0 Cr | 9.1% | 18.2% | 47.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,515.0 Cr | 3.6% | 3.4% | 36.4% | Stock Analytics | |
| CIPLA | ₹114,554.0 Cr | -1.2% | -3.3% | -10.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,308.6 Cr | -1.4% | 2.9% | -8% | Stock Analytics | |
COHANCE LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| COHANCE LIFESCIENCES | 0.4% |
5.9% |
-48.7% |
| SENSEX | -0.4% |
-0.5% |
-5.8% |
You may also like the below Video Courses
